CimCure focuses on design and development of a novel class of active cancer immunotherapies.
CimCure has raised $5.3M in total funding. The most recent round was Seed. The last funding was announced in June 2022.
CimCure's investors include Positron Ventures, Tom Würdinger.
CimCure is headquartered in Amsterdam, The Netherlands.
CimCure focuses on design and development of a novel class of active cancer immunotherapies.
CimCure is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CimCure — Funding & Investors." VCBacked, June 7, 2022, https://www.vcbacked.co/company/cimcure. Accessed September 30, 2026.
VCBacked. (2022). CimCure — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cimcure
{{cite web |title=CimCure — Funding & Investors |url=https://www.vcbacked.co/company/cimcure |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated